Related Experiment Videos
Myopathy during amiodarone treatment: a case report
Italian Journal of Neurological Sciences
|December 1, 1987
Summary
Chronic amiodarone treatment can cause muscle weakness due to drug accumulation in tissues. Muscle biopsy revealed significant amiodarone levels, suggesting tissue concentration, not blood levels, drives toxicity.
Area of Science:
- Pharmacology
- Neurology
- Toxicology
Background:
- Amiodarone is an antiarrhythmic drug used for cardiac rhythm disorders.
- Chronic amiodarone use is associated with various side effects.
- Muscle weakness is a potential adverse effect of amiodarone therapy.
Observation:
- A 69-year-old woman experienced progressive muscle weakness during long-term amiodarone treatment.
- Muscle biopsy revealed characteristic vacuolar alterations.
- Significant accumulation of amiodarone and its metabolite, desethylamiodarone, was detected in muscle tissue.
Findings:
- Muscle tissue concentrations of amiodarone and desethylamiodarone were markedly elevated.
- These tissue levels were high despite the patient having normal blood concentrations of the drug.
- The findings suggest a disconnect between serum levels and tissue burden of amiodarone.
Implications:
- Amiodarone-induced myopathy may be linked to drug accumulation within muscle cells.
- Monitoring tissue drug levels, rather than solely blood levels, could be crucial for assessing toxicity risk.
- This case highlights the importance of considering localized tissue pharmacokinetics in drug-induced adverse events.